Literature DB >> 26648639

Managing obsessive compulsive disorder.

Vlasios Brakoulias1.   

Abstract

Unlike obsessive compulsive personality traits or occasional repetitive habits, obsessive compulsive disorder can be highly distressing and associated with significant disability. Treatment should always be offered. Psychological interventions and selective serotonin reuptake inhibitors are first-line treatments for obsessive compulsive disorder. Patients with obsessive compulsive disorder respond to selective serotonin reuptake inhibitors at a slower rate than those with depression. The dose of a selective serotonin reuptake inhibitor can be increased at two-week intervals depending on the patient's response. Aim for doses in the higher therapeutic range. Improvements from treatment usually plateau at 12 weeks. Successful treatment should continue for at least 12 months. There is a significant risk of relapse when treatment is stopped.

Entities:  

Keywords:  antidepressants; anxiety disorders; cognitive behavioural therapy; obsessive compulsive disorder

Year:  2015        PMID: 26648639      PMCID: PMC4653979          DOI: 10.18773/austprescr.2015.040

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  13 in total

1.  Interpersonal reassurance seeking in obsessive-compulsive disorder and its relationship with checking compulsions.

Authors:  Vladan Starcevic; David Berle; Vlasios Brakoulias; Peter Sammut; Karen Moses; Denise Milicevic; Anthony Hannan
Journal:  Psychiatry Res       Date:  2012-07-07       Impact factor: 3.222

Review 2.  Treatment of obsessive compulsive disorder.

Authors:  Martin E Franklin; Edna B Foa
Journal:  Annu Rev Clin Psychol       Date:  2011       Impact factor: 18.561

3.  Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.

Authors:  Deborah L Ackerman; Sander Greenland
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

4.  Response versus remission in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Jonathan D Huppert; Eva Petkova; Edna B Foa; Michael R Liebowitz
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

5.  High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.

Authors:  Philip T Ninan; Lorrin M Koran; Ari Kiev; Jonathan R T Davidson; Steven A Rasmussen; John M Zajecka; Delbert G Robinson; Paul Crits-Christoph; Francine S Mandel; Carol Austin
Journal:  J Clin Psychiatry       Date:  2006-01       Impact factor: 4.384

6.  Obsessive--compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population.

Authors:  Mythily Subramaniam; Edimansyah Abdin; Janhavi Ajit Vaingankar; Siow Ann Chong
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-04-17       Impact factor: 4.328

7.  A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.

Authors:  G D Tollefson; A H Rampey; J H Potvin; M A Jenike; A J Rush; R A kominguez; L M Koran; M K Shear; W Goodman; L A Genduso
Journal:  Arch Gen Psychiatry       Date:  1994-07

8.  Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.

Authors:  H Blair Simpson; Michael R Liebowitz; Edna B Foa; Michael J Kozak; Andrew B Schmidt; Vivienne Rowan; Eva Petkova; Kevin Kjernisted; Jonathan D Huppert; Martin E Franklin; Sharon O Davies; Raphael Campeas
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

9.  A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.

Authors:  J H Greist; J W Jefferson; K A Kobak; G Chouinard; E DuBoff; A Halaris; S W Kim; L Koran; M R Liebowtiz; B Lydiard
Journal:  Int Clin Psychopharmacol       Date:  1995-06       Impact factor: 1.659

Review 10.  Treatment strategies for obsessive-compulsive disorder.

Authors:  Donatella Marazziti; Giorgio Consoli
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

View more
  3 in total

Review 1.  Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines.

Authors:  Cody J Connor
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-04-20

2.  Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial.

Authors:  Sophia Esalatmanesh; Mojtaba Biuseh; Ahmad Ali Noorbala; Seyed-Ali Mostafavi; Farzin Rezaei; Bita Mesgarpour; Payam Mohammadinejad; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2017-07

Review 3.  Bidirectional Behavioral Selection in Mice: A Novel Pre-clinical Approach to Examining Compulsivity.

Authors:  Swarup Mitra; Abel Bult-Ito
Journal:  Front Psychiatry       Date:  2021-09-08       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.